专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050152848A1 Pulmonary administration of chemically modified insulin 审中-公开
公开(公告)号：US20050152848A1
公开(公告)日：2005-07-14
申请号：US10980652
申请日：2004-11-02
申请人： John Patton , Mei-Chang Kuo , J. Harris , Chester Leach , Kimberly Perkins , Blaine Bueche
发明人： John Patton , Mei-Chang Kuo , J. Harris , Chester Leach , Kimberly Perkins , Blaine Bueche
IPC分类号： A61K9/08 , A61K9/12 , A61K9/19 , A61K9/24 , A61K9/72 , A61K38/00 , A61K38/16 , A61K38/28 , A61K47/34 , A61K47/48 , A61L9/04 , A61P3/10 , C07K14/62 , A61K9/14
CPC分类号： A61K38/28 , A61K47/60
摘要： The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.

2. 发明授权

US06890518B2 Compositions of chemically modified insulin 失效
标题翻译：化学修饰胰岛素的组成
公开(公告)号：US06890518B2
公开(公告)日：2005-05-10
申请号：US10405190
申请日：2003-04-01
申请人： John S. Patton , Mei-Chang Kuo , J. Milton Harris , Chester Leach , Kimberly Perkins , Blaine Bueche
发明人： John S. Patton , Mei-Chang Kuo , J. Milton Harris , Chester Leach , Kimberly Perkins , Blaine Bueche
IPC分类号： A61K9/08 , A61K9/12 , A61K9/19 , A61K9/24 , A61K9/72 , A61K38/00 , A61K38/16 , A61K38/28 , A61K47/34 , A61K47/48 , A61L9/04 , A61P3/10 , C07K14/62
CPC分类号： A61K38/28 , A61K47/60
摘要： The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
摘要翻译：本发明提供胰岛素的活性亲水性聚合物改性衍生物。在一个方面，本发明的胰岛素衍生物适合于递送至肺并表现出比天然胰岛素明显改善的药物动力学和/或药效学性质。

3. 发明授权

US06838076B2 Pulmonary administration of chemically modified insulin 失效
标题翻译：肺部给予化学修饰的胰岛素
公开(公告)号：US06838076B2
公开(公告)日：2005-01-04
申请号：US10154057
申请日：2002-05-21
申请人： John S. Patton , Mei-Chang Kuo , J. Milton Harris , Chester Leach , Kimberly Perkins , Blaine Bueche
发明人： John S. Patton , Mei-Chang Kuo , J. Milton Harris , Chester Leach , Kimberly Perkins , Blaine Bueche
IPC分类号： A61K9/08 , A61K9/12 , A61K9/19 , A61K9/24 , A61K9/72 , A61K38/00 , A61K38/16 , A61K38/28 , A61K47/34 , A61K47/48 , A61L9/04 , A61P3/10 , C07K14/62
CPC分类号： A61K38/28 , A61K47/60
摘要： The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
摘要翻译：本发明提供胰岛素的活性亲水性聚合物改性衍生物。在一个方面，本发明的胰岛素衍生物适合于递送至肺并表现出比天然胰岛素明显改善的药物动力学和/或药效学性质。

4. 发明申请

US20060018840A1 Aerosolizable formulation comprising nicotine 审中-公开
标题翻译：包含尼古丁的可气雾化制剂
公开(公告)号：US20060018840A1
公开(公告)日：2006-01-26
申请号：US11169153
申请日：2005-06-28
申请人： David Lechuga-Ballesteros , Mei-Chang Kuo , Yuan Song , Blaine Bueche
发明人： David Lechuga-Ballesteros , Mei-Chang Kuo , Yuan Song , Blaine Bueche
IPC分类号： A61L9/04 , A01N43/40 , A61K31/4439
CPC分类号： A61K9/008 , A01N43/40 , A61K31/4439 , A61K31/465 , A01N37/36 , A01N37/02 , A01N25/06 , A01N25/02 , A01N2300/00
摘要： An aerosolizable formulation comprises free-base nicotine, an organic acid, and a hydrofluoroalkane propellant. The organic acid is present in a mole ratio with said nicotine in a range of about 0.25:1 (organic acid:nicotine) to about 4:1 (organic acid:nicotine). The organic acid and said free-base nicotine form a nicotine salt. An equivalent mixture of free-base nicotine and organic acid in water has a pH between about pH 3.0 and about pH 9.0. The aerosolizable formulation is aerosolizable, for example, by a metered dose inhaler for administration to a user.
摘要翻译：可雾化的制剂包含游离碱尼古丁，有机酸和氢氟烷烃推进剂。有机酸以约0.25:1（有机酸：尼古丁）至约4:1（有机酸：尼古丁）的范围内与所述尼古丁的摩尔比存在。有机酸和游离碱尼古丁形成尼古丁盐。游离碱尼古丁和有机酸在水中的等效混合物的pH在约pH3.0和约pH9.0之间。可雾化制剂可雾化，例如通过用于给用户施用的计量吸入器。

5. 发明申请

US20110171312A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE 审中-公开
标题翻译：改性治疗肽，其制备和使用方法
公开(公告)号：US20110171312A1
公开(公告)日：2011-07-14
申请号：US13119208
申请日：2009-09-17
申请人： Mei-Chang Kuo , Blaine Bueche , Mary J. Bossard , Cindy L. Barnes
发明人： Mei-Chang Kuo , Blaine Bueche , Mary J. Bossard , Cindy L. Barnes
IPC分类号： A61K9/14 , A61K38/28 , C07K14/62 , A61P3/10
CPC分类号： C07K14/62 , A61K47/542 , A61K47/60
摘要： Modified therapeutic peptide compositions comprising conjugates of therapeutic peptides covalently coupled to one or more hydrophilic polymers. Optionally, the therapeutic peptide is also covalently coupled to one or more moieties having one to ten carbon atoms. Methods of making and use are also provided. The conjugates, when administered by any of a number of administration routes, exhibit characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer and/or one or moiety having one to ten carbon atoms.
摘要翻译：修饰的治疗性肽组合物包含与一种或多种亲水性聚合物共价偶联的治疗性肽的缀合物。任选地，治疗性肽还共价偶联至一个或多个具有1-10个碳原子的部分。还提供了制作和使用的方法。缀合物当通过许多给药途径中的任一种施用时，显示出与未附着于水溶性低聚物和/或具有1-10个碳原子的一个或多个部分的肽的特征不同的特征。

6. 发明申请

US20100210676A1 Chemically Modified Small Molecules 有权
标题翻译：化学改性的小分子
公开(公告)号：US20100210676A1
公开(公告)日：2010-08-19
申请号：US12710167
申请日：2010-02-22
申请人： C. Simone Fishburn , David Lechuga-Ballesteros , Tacey Viegas , Mei-Chang Kuo , Yuan Song , Hema Gursahani , Chester Leach
发明人： C. Simone Fishburn , David Lechuga-Ballesteros , Tacey Viegas , Mei-Chang Kuo , Yuan Song , Hema Gursahani , Chester Leach
IPC分类号： A61K31/485 , A61P25/36
CPC分类号： A61K9/007 , A61K31/167 , A61K31/485 , A61K47/60 , C07C41/24
摘要： Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
摘要翻译：通过肺途径改变施用于受试者的药物的全身吸收速率的方法，所述方法包括将亲水性聚合物与药物共价共轭，其中所述药物具有从肺中消除的半衰期小于约180 分钟，以形成药物 - 聚合物缀合物，其中药物 - 聚合物缀合物具有净亲水特性和约50至约20,000道尔顿的重均分子量，并且其中从药物的肺中消除的半衰期 - 聚合物缀合物比从药物肺消除的半衰期大至少约1.5倍，其中通过支气管肺泡灌洗测量肺部消除的半衰期，然后测定残留的肺部材料。

7. 发明申请

US20120088745A1 CHEMICALLY MODIFIED SMALL MOLECULES 审中-公开
标题翻译：化学改性的小分子
公开(公告)号：US20120088745A1
公开(公告)日：2012-04-12
申请号：US13271158
申请日：2011-10-11
申请人： C. Simone Fishburn , David Lechuga-Ballesteros , Tacey Viegas , Mei-Chang Kuo , Yuan Song , Hema Gursahani , Chester Leach
发明人： C. Simone Fishburn , David Lechuga-Ballesteros , Tacey Viegas , Mei-Chang Kuo , Yuan Song , Hema Gursahani , Chester Leach
IPC分类号： A61K31/16 , C07D489/08 , C07C43/13 , C07J5/00 , A61K31/573 , C07C233/21 , A61K31/485
CPC分类号： A61K9/007 , A61K31/167 , A61K31/485 , A61K47/60 , C07C41/24
摘要： Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
摘要翻译：通过肺途径改变施用于受试者的药物的全身吸收速率的方法，所述方法包括将亲水性聚合物与药物共价共轭，其中所述药物具有从肺中消除的半衰期小于约180 分钟，以形成药物 - 聚合物缀合物，其中药物 - 聚合物缀合物具有净亲水特性和约50至约20,000道尔顿的重均分子量，并且其中从药物的肺中消除的半衰期 - 聚合物缀合物比从药物肺消除的半衰期大至少约1.5倍，其中通过支气管肺泡灌洗测量肺部消除的半衰期，然后测定残留的肺部材料。

8. 发明授权

US08067431B2 Chemically modified small molecules 有权
标题翻译：化学修饰的小分子
公开(公告)号：US08067431B2
公开(公告)日：2011-11-29
申请号：US12710167
申请日：2010-02-22
申请人： C. Simone Fishburn , David Lechuga-Ballesteros , Tacey Viegas , Mei-Chang Kuo , Yuan Song , Hema Gursahani , Chester Leach
发明人： C. Simone Fishburn , David Lechuga-Ballesteros , Tacey Viegas , Mei-Chang Kuo , Yuan Song , Hema Gursahani , Chester Leach
IPC分类号： A61K31/485 , C07D489/08
CPC分类号： A61K9/007 , A61K31/167 , A61K31/485 , A61K47/60 , C07C41/24
摘要： Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
摘要翻译：通过肺途径改变施用于受试者的药物的全身吸收速率的方法，所述方法包括将亲水性聚合物与药物共价共轭，其中所述药物具有从肺中消除的半衰期小于约180 分钟，以形成药物 - 聚合物缀合物，其中药物 - 聚合物缀合物具有净亲水特性和约50至约20,000道尔顿的重均分子量，并且其中从药物的肺中消除的半衰期 - 聚合物缀合物比从药物肺消除的半衰期大至少约1.5倍，其中通过支气管肺泡灌洗测量肺部消除的半衰期，然后测定残留的肺部材料。

9. 发明申请

US20060182692A1 Chemically modified small molecules 审中-公开
标题翻译：化学修饰的小分子
公开(公告)号：US20060182692A1
公开(公告)日：2006-08-17
申请号：US11344404
申请日：2006-01-30
申请人： C. Fishburn , David Lechuga-Ballesteros , Tacey Viegas , Mei-Chang Kuo , Yuan Song , Hema Gursahani , Chester Leach
发明人： C. Fishburn , David Lechuga-Ballesteros , Tacey Viegas , Mei-Chang Kuo , Yuan Song , Hema Gursahani , Chester Leach
IPC分类号： A61K9/14 , A61L9/04
CPC分类号： A61K9/007 , A61K31/167 , A61K31/485 , A61K47/60 , C07C41/24
摘要： Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
摘要翻译：通过肺途径改变施用于受试者的药物的全身吸收速率的方法，所述方法包括将亲水性聚合物与药物共价共轭，其中所述药物具有从肺中消除的半衰期小于约180 分钟，以形成药物 - 聚合物缀合物，其中药物 - 聚合物缀合物具有净亲水特性和约50至约20,000道尔顿的重均分子量，并且其中从药物的肺中消除的半衰期 - 聚合物缀合物比从药物肺消除的半衰期大至少约1.5倍，其中通过支气管肺泡灌洗测量肺部消除的半衰期，然后测定残留的肺部材料。

10. 发明授权

US08540999B2 Allergenic proteins and peptides from Japanese cedar pollen 有权
标题翻译：来自日本雪松花粉的过敏蛋白和肽
公开(公告)号：US08540999B2
公开(公告)日：2013-09-24
申请号：US10931260
申请日：2004-08-30
申请人： Irwin J. Griffith , Joanne Pollock , Julian F. Bond , Richard D. Garman , Mei-Chang Kuo , Stephen P. Powers , Mark A. Exley , Xian Chen , Ze'ev Shaked
发明人： Irwin J. Griffith , Joanne Pollock , Julian F. Bond , Richard D. Garman , Mei-Chang Kuo , Stephen P. Powers , Mark A. Exley , Xian Chen , Ze'ev Shaked
IPC分类号： A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , C07K1/00 , C07K14/00 , C07K17/00
CPC分类号： C07K14/415 , A61K38/00 , A61K39/00 , C07K16/16
摘要： The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding naturally-occurring allergen or portion thereof but having reduced side effects. Methods of treatment or of diagnosis of sensitivity to Japanese cedar pollens in an individual and therapeutic compositions, and multipeptide formulations comprising one or more peptides of the invention are also provided.
摘要翻译：本发明提供了编码粳稻主要花粉过敏原Cryj I，Cryj II，Jun s I和Jun v I的核酸序列及其片段或肽。本发明还提供纯化的Cry j I，Cryj II，Jun s I和Jun v I，以及在用编码Cryj I，Cryj II，Jun的核酸序列转化的宿主细胞中产生的至少一个片段 I和Jun v I或其至少一个片段，以及Cry j I，Cry j II，Jun s I或Jun v I或其至少一个片段的片段，以及Cryj I，Cryj II，Jun 我或Jun v我合成了。 Cry j I，Cry j II，Jun s I和Jun v I及其片段可用于诊断，治疗和预防日本雪松花粉病。本发明还提供了Cryj I和Cryj II的分离的肽。本发明范围内的肽包含至少一个T细胞表位，或优选至少两个Cryj I或Cryj II的T细胞表位。本发明还涉及与相应的天然存在的变应原或其部分具有相似或增强的治疗性质但具有减少的副作用的改性肽。还提供了治疗或诊断个体对日本雪松花粉和治疗组合物的方法，以及包含一种或多种本发明的肽的多肽制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式